PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3)
dated September 20, 2000 Registration No. 333-36318
to Prospectus dated August 2, 2000
$200,000,000
INCYTE GENOMICS, INC.
5.5% CONVERTIBLE SUBORDINATED NOTES DUE 2007
and
SHARES OF COMMON STOCK
ISSUABLE UPON CONVERSION OF THE NOTES
This prospectus supplement relates to the resale by the holders of 5.5%
convertible subordinated notes due 2007 of Incyte Genomics, Inc. and the shares
of common stock issuable upon conversion of the notes.
This prospectus supplement should be read in conjunction with the
prospectus dated August 2, 2000, which is to be delivered with this prospectus
supplement.
The information in the table appearing under the heading "Selling
Securityholders" in the prospectus is supplemented and superseded in part by the
information appearing in the table below:
<TABLE>
<CAPTION>
Principal Common Stock
Amount of Notes Common Stock Owned After
Beneficially Issuable Upon Completion
Owned and Conversion Common Stock of the
Name Offered(1) of the Notes(1) Offered(1) Offering(1)
---- --------------- --------------- ------------ ------------
<S> <C> <C> <C> <C>
Alta Partners Holdings, LDC.................... $3,500,000 25,956 25,956 --
Bank America Pension Plan...................... $2,650,000 19,653 19,653 --
Circlet (IMA) Limited.......................... $3,000,000 22,248 22,248 --
Credit Suisse First Boston Corporation......... $100,000 741 741 --
Deeprock & Co. ................................ $3,000,000 22,248 22,248 --
Duckbill & Co. ................................ $2,500,000 18,540 18,540 --
General Motors Welfare Benefit Trust (L-T Veba) $2,000,000 14,832 14,832 --
General Motors Welfare Benefit Trust (S-T Veba) $2,500,000 18,540 18,540 --
Pine Grove Enhanced Partners, L.P. ............ $500,000 3,708 3,708 --
Retail Clerks Pension Trust #2................. $2,000,000 14,832 14,832 --
----------------------
<FN>
(1) Amounts indicated may be in excess of the total amount registered due
to sales or transactions exempt from the registration requirements of the
Securities Act of 1933 since the date on which selling securityholders provided
information to us regarding their notes.
None of the selling securityholders listed above nor any of their
affiliates, officers, directors or principal equity holders has held any
position or office or has had any material relationship with us within the past
three years.
</FN>
</TABLE>
--------------------
Investing in the notes and our common stock involves a high degree of risk.
You should carefully read and consider the "Risk Factors" beginning on page 3 of
the prospectus.
--------------------
<PAGE>
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus supplement or the prospectus. Any
representation to the contrary is a criminal offense.
Page 2 to Prospectus Supplement dated September 20, 2000
